Summary

Eligibility
for people ages 2-22 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).

Official Title

A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Keywords

SCN8A Developmental and Epileptic Encephalopathy Syndrome, Epilepsy, Sodium channel, voltage-gated, type VIII, alpha subunit (SCN8A), NaV1.6 inhibitor, Brain Diseases, Syndrome, NBI-921352

Eligibility

Locations

  • UCSF Medical Center
    San Francisco California 94143 United States
  • Cook Children's Medical Center
    Fort Worth Texas 76104 United States
  • University of Rochester
    Rochester New York 14642 United States
  • Children's National Hospital
    Washington District of Columbia 20010 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Neurocrine Biosciences
ID
NCT05226780
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 8 people participating
Last Updated